Compare COLD & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLD | TVTX |
|---|---|---|
| Founded | 1903 | N/A |
| Country | United States | United States |
| Employees | 12690 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.3B |
| IPO Year | 2009 | 2013 |
| Metric | COLD | TVTX |
|---|---|---|
| Price | $14.59 | $67.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $14.97 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 3.1M | 1.6M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 7.67% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,601,846,000.00 | N/A |
| Revenue This Year | N/A | $44.76 |
| Revenue Next Year | $2.86 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $19.46 |
| 52 Week High | $16.88 | $67.85 |
| Indicator | COLD | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 64.48 |
| Support Level | $13.84 | $53.76 |
| Resistance Level | $15.45 | N/A |
| Average True Range (ATR) | 0.37 | 1.98 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 17.39 | 89.97 |
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.